OrthoPediatrics Corp. achieved an all-time high full year 2025 Revenue of $236.1 million, showing a growth of 15% over the previous year.
The Company helped over 37,500 children in the fourth quarter of 2025, totaling nearly 1.3 million children helped since inception.
They generated record preliminary unaudited full year 2025 net revenue, with domestic net revenue expected to be $186.2 million and international net revenue expected to be $49.9 million.
Revenue Growth
15% growth in full year 2025 revenue compared to 2024.
Free Cash Flow
Generated approximately $6.0 - $7.0 million dollars of fourth quarter 2025 free cash flow, with total year 2025 free cash flow usage being over 50% lower than the previous year.
2026 Guidance
Projected 2026 revenue in the range of $262 million to $266 million, expecting 11% to 13% growth compared to 2025.
- The Company's strong performance in 2025 showcased their leadership in pediatric orthopedics and strategic initiatives.
- OrthoPediatrics' Trauma and Deformity and Scoliosis implant businesses gained market share and improved profitability.
- Specialty bracing (OPSB) business proved to be a strategic catalyst for revenue and earnings growth.
OrthoPediatrics' continued growth drivers and operational discipline position them to execute their long-term outlook and make a meaningful impact for children worldwide.